Selvita, an integrated service provider aiming to deliver a set of comprehensive solutions supporting customers and projects within area of drug discovery and drug development, has announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development. To achieve this objective, the company will open a new research site in Wrocław, where it will contract highly experienced scientists. The announcement comes after in 2023 the company generated sales revenue of PLN346.95m, EBITDA of PLN126.27m and a net profit of ca. PLN70m. (ICE VARSAVIA)

Fonte notizia: wnp.pl